<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medications for management of acute opioid withdrawal in adults in the emergency setting</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medications for management of acute opioid withdrawal in adults in the emergency setting</h1>
<div class="graphic"><div class="figure"><div class="ttl">Medications for management of acute opioid withdrawal in adults in the emergency setting</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Medication</td> <td class="subtitle1">Initial dose (adult)</td> <td class="subtitle1">Indication</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Opioid</td> </tr> <tr> <td class="indent1">Methadone</td> <td> <p>10 mg IM or 20 mg orally (for patient not currently taking methadone)</p> May give an additional half-dose if significant withdrawal symptoms persist 1 hour after IM dose or 2 hours after oral dose; maximum in first 24 hours: 20 mg IM or 40 mg orally</td> <td> <ul> <li>Acute opioid withdrawal.*</li> <li><strong>Not</strong> recommended for management of acute withdrawal triggered by an opioid antagonist (naloxone, naltrexone, nalmefene).</li> <li>May prolong QTc interval; refer to clinical topic for ECG screening indications.</li> </ul> </td> </tr> <tr> <td class="indent1">Buprenorphine</td> <td> <p><strong>Standard initiation</strong> (NOTE: Before beginning this regimen, patient needs to have entered mild-moderate withdrawal generally with COWS score &gt;8): starting dose is typically 8 mg sublingually<sup>¶</sup>; if withdrawal persists 30 to 60 minutes later, can give additional 8 mg doses every 1 or more hours, up to 32 mg total in 24 hours, but higher doses are occasionally required</p> <p class="extra_spacing"><strong>or</strong></p> 0.3 to 0.9 mg IV every 6 to 12 hours <p class="extra_spacing_top"><strong>Alternative low-dose initiation</strong> "microdosing" (NOTE: Can begin <strong>without</strong> waiting for onset of withdrawal signs): 0.5 to 2 mg SL with frequent (eg, every 1 to 2 hours) redosing<sup>¶</sup></p> </td> <td> <ul> <li>Acute opioid withdrawal.*</li> <li>Alternative low-dose initiation may be preferred for treating individuals who are not yet having signs of withdrawal, with high levels of opioid dependence, cannot abstain from opioid use long enough to tolerate a standard induction, or when transitioning from methadone to buprenorphine.</li> <li>If used to manage acute withdrawal triggered by an opioid antagonist (naloxone, naltrexone, nalmefene), the buprenorphine dose should be tailored to the agent and the dose that precipitated the withdrawal.</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="3">Non-opioid adjunctive medications*</td> </tr> <tr> <td class="indent1">Clonidine</td> <td>0.1 to 0.3 mg orally every hour with monitoring of blood pressure and heart rate (0.8 mg maximum total daily dose); check blood pressure prior to each dose and hold the dose if hypotension is present</td> <td rowspan="2"> <ul> <li>Anxiety, restlessness, dysphoria with elevated or normal blood pressure and heart rate.</li> </ul> </td> </tr> <tr> <td class="indent1">Lofexidine</td> <td>0.54 mg orally every 5 to 6 hours as needed; maximum 2.88 mg/24 hours</td> </tr> <tr> <td class="indent1">Diazepam</td> <td> <p>5 to 10 mg orally or IV; may repeat after 5 to 10 minutes until symptoms subside</p> Alternative benzodiazepines if diazepam not available: <ul class="decimal_heading"> <li>Lorazepam 1 to 2 mg IV may be given every 10 minutes until symptoms subside</li> <li>Midazolam 2 mg IV may be given every 5 to 10 minutes until symptoms subside</li> </ul> <p class="extra_spacing_top">Hold doses if patient does not remain hemodynamically stable</p> </td> <td> <ul> <li>Hypertension and tachycardia precipitated by long-acting antagonist (eg, naltrexone, nalmefene).</li> <li>Anxiety, restlessness, dysphoria, insomnia, muscle cramping.</li> </ul> </td> </tr> <tr> <td class="indent1">Ondansetron</td> <td>4 to 8 mg IV or IM; 8 mg ODT or orally; every 4 to 8 hours as needed</td> <td rowspan="3"> <ul> <li>Nausea, vomiting.</li> </ul> </td> </tr> <tr> <td class="indent1">Diphenhydramine</td> <td>50 mg IV, IM, or orally every 6 hours as needed</td> </tr> <tr> <td class="indent1">Hydroxyzine</td> <td>50 to 100 mg IM or orally every 6 hours as needed</td> </tr> <tr> <td class="indent1">Loperamide</td> <td>4 mg orally, followed by 2 mg every loose stool; maximum: 16 mg/24 hours</td> <td rowspan="3"> <ul> <li>Diarrhea, stomach cramps.</li> </ul> </td> </tr> <tr> <td class="indent1">Octreotide</td> <td>50 micrograms SUBQ every 6 hours as needed</td> </tr> <tr> <td class="indent1">Bismuth subsalicylate</td> <td>524 mg orally every 30 to 60 minutes as needed; maximum 4200 mg/24 hours</td> </tr> <tr> <td class="indent1">Acetaminophen</td> <td>650 to 1000 mg orally every 4 to 6 hours as needed; maximum 4000 mg/24 hours</td> <td rowspan="2"> <ul> <li>Pain, myalgia.</li> </ul> </td> </tr> <tr> <td class="indent1">Ibuprofen</td> <td>600 mg orally every 6 to 8 hours as needed; maximum 2400 mg/24 hours</td> </tr> <tr> <td class="indent1">Baclofen</td> <td>5 to 10 mg orally up to three times per day</td> <td> <ul> <li>Muscle cramping.</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">For additional information on managing symptoms of withdrawal in patients cared for in a non-emergency setting, refer to the UpToDate topics discussing treatment of opioid use disorder. The approach to treatment of iatrogenic withdrawal (eg, weaning from prolonged opioid infusions) is reviewed separately; refer to UpToDate topic reviews of opioid withdrawal in critically ill patients.</div><div class="graphic_footnotes"><p>IM: intramuscular; ECG: electrocardiogram; COWS: Clinical Opiate Withdrawal Scale; IV: intravenous; SUBQ: subcutaneous; SL: sublingual; ODT: orally disintegrating tablet.</p>
<p>* Opioids are generally more effective than non-opioid adjunctive medications and should be offered to patients with opioid withdrawal. Refer to UpToDate topics on opioid withdrawal in adults.</p>
¶ Buprenorphine buccal film has greater bioavailability compared with sublingual tablets and film. 450 mcg buccal buprenorphine ≈ 1 mg SL buprenorphine.</div><div id="graphicVersion">Graphic 54978 Version 17.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
